<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Stocks sold Thursday after being reinforced by weak data from manufacturing worries slowdown in economic growth & nbsp;Dow Jones Industrial Average (DJINDICES: ^ DJI)& nbsp; and the & nbsp;S & amp; P 500 (SNPINDEX: ^ GSPC)& nbsp; opened down, seemed to be bouncing around noon, but fell in the afternoon to get closer to his lows for the session. "data-reactid =" 11 "> The shares sold on Thursday after weak manufacturing data in the US raised concerns about slowing economic growth. Dow Jones Industrial Average (DJINDICES: ^ DJI) and the S & P 500 (SNPINDEX: ^ GSPC) opened down, seemed to attempt a bounce around noon, but fell in the afternoon to get close to its lows for the session.

Stock exchange today

Percentage change in the index of change of the Dow Exchange Index (2.83%) (660.02) S & P 500 (2.48%) (62.14)

Data source: Yahoo! Finance.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Technological actions have been hammered, with the & nbsp;Selected technology sector SPDR ETF (NYSEMKT: XLK) lose 5.1%. Gold has been rising since mid-November as investors seek safe havens. the & nbsp;ETF VanEck Vectors Junior Gold Miners (NYSEMKT: GDXJ) gained 3.7%. & nbsp; "data-reactid =" 16 "> Technological shares were hammered, the Selected technology sector SPDR ETF (NYSEMKT: XLK) losing 5.1%. Gold has been rising since mid-November as investors seek safe havens. the ETF VanEck Vectors Junior Gold Miners (NYSEMKT: GDXJ) gained 3.7%.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "As for individual actions, Apple (NASDAQ: AAPL) caused market anxiety when it reduced its sales forecast and Bristol-Myers Squibb (NYSE: BMY) announced its intention to buy & nbsp;Celgene"data-reactid =" 17 "> For individual stocks, Apple (NASDAQ: AAPL) has raised market concerns by reducing its sales forecast and Bristol-Myers Squibb (NYSE: BMY) announced plans to buy Celgene.

Red arrow down on coins and columns of numbers.

More

Source of the image: Getty Images.

Apple disappointed by the disappointing sales of the iPhone

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Apple's stock fell 10% after the issuance of the company a downward revision of its indications for his first fiscal quarter because of weak Chinese sales of iPhone and slower iPhone upgrades in developed markets. In a rare reduction in previously published sales forecasts, Apple said it expects a turnover of $ 84 billion for the quarter ended Dec. 29, or 7.7 percent below average from his predictions of two months ago. & Nbsp; "data-reactid =" 31 "> Apple's shares fell 10% after the company published a downward revision of its guidance for the first quarter of its fiscal year due to weak iPhone sales in China and the slowdown of iPhone upgrades in developed markets, said it expects $ 84 billion in sales in the quarter ended December 29, or 7.7% less than the average predicted by its predictions two months ago.

<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The new forecast represents a decrease in revenues of 4.9 Apple has blamed the unexpected shortfall in iPhone sales, saying non-iPhone revenue has increased by almost 19% and revenue from service company 27.5% increase. & nbsp; "data-reactid =" 32 "> This new forecast represents a 4.9% decline in revenue compared to the first quarter of last year.Appendering Apple totally unexpected revenue shortfall in sales of the iPhone, claiming that revenue excluding iPhone grew by almost 19% and revenue from its services business grew by 27.5%.

Statements arousing concern about an economic slowdown in China have hurt the market in general, commented CEO, Tim Cook, "[W]We have not foreseen the extent of the economic slowdown, especially in Greater China. "The clues that the Chinese consumer is affected by rising trade tensions are weighing on the market as a whole.

Bristol-Myers Squibb aims to take Celgene

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Bristol-Myers Squibb launched 2019 by announcing a massive acquisition, & nbsp; Provides Celgene with $ 74 billion in combined cash and equity to become a cancer treatment giant. Investors were skeptical, sending Bristol-Myers Squibb shares down 13.3%. "Data-reactid =" 35 "> Bristol-Myers Squibb launched 2019 by announcing a massive acquisition offering Celgene $ 74 billion in cash and equities Investors were skeptical and sold 13.3% of Bristol shares -Myers Squibb.

Bristol-Myers will pay $ 50 in cash plus a share of its shares for each share of Celgene. In addition, Celgene shareholders will receive a negotiable TRQ for each Celgene share, which will result in a payment of US $ 9 upon approval of three Celgene drugs by the FDA. Based on yesterday's closing prices, the transaction values ​​Celgene shares at $ 102.43, a premium of 54%.

<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The merged company will be the # 1 biopharmaceutical company in oncology and cardiovascular drugs & nbsp; and in the top 5 in immunology & inflammation. The growth of Bristol-Myers, the acquisition is expected to generate a 40% increase in earnings per share and cost savings of $ 2.5 billion by 2022. The combined company will have nine flagship drugs and short-term drug product launches. revenue opportunity of $ 15 billion. "data-reactid =" 37 "> The merged company will be the first biopharmaceutical company in the field of oncology and cardiovascular drugs, as well as in the top five for immunology and inflammation. growth in Bristol-Myers, with a $ 2.5 billion increase in earnings per share and cost savings by 2022. The combined company will have nine blockbuster drugs and short-term drug launches as a source of revenues of $ 15 billion.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " More from The Motley Fool "data-reactid =" 38 "> More from The Motley Fool

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Jim Crumly holds shares in Apple and CELG. The Motley Fool owns shares and recommends Apple and CELG. The Motley Fool offers the following options: long calls from $ 150 to January 2020 for Apple and $ 155 short calls from January 2020 to Apple. The Motley Fool has a disclosure policy."data-reactid =" 46 ">Jim Crumly owns shares in Apple and CELG. The Motley Fool owns shares and recommends Apple and CELG. The Motley Fool offers the following options: long calls from $ 150 to January 2020 for Apple and $ 155 short calls from January 2020 to Apple. Motley Fool has a disclosure policy.